Phase II Single Center Open-Label Single-Arm Study of the Safety and Efficacy of Oncolytic Adenovirus H101 Combined With PD-1 Inhibitor in Patients With Non-muscle-invasive Bladder Cancer Who Failed BCG Therapy
Latest Information Update: 06 Oct 2022
At a glance
- Drugs Camrelizumab (Primary) ; H-101 (Primary) ; H-101 (Primary)
- Indications Bladder cancer
- Focus Therapeutic Use
Most Recent Events
- 06 Oct 2022 New trial record